Down-regulated expression of plant-specific glycoepitopes in alfalfa |
| |
Authors: | Sourrouille Christophe Marquet-Blouin Estelle D'Aoust Marc-André Kiefer-Meyer Marie-Christine Seveno Martial Pagny-Salehabadi Sophie Bardor Muriel Durambur Gaelle Lerouge Patrice Vezina Louis Gomord Véronique |
| |
Affiliation: | CNRS UMR 6037, IFRMP 23, GDR 2590, Universitéde Rouen, 76821 Mont Saint Aignan, France; Medicago Inc, 1020 Route de l'église, Bureau 600, Quebec, QC, Canada, G1V 3V9 |
| |
Abstract: | Compared with other plant expression systems used for pharmaceutical protein production, alfalfa offers the advantage of very homogeneous N -glycosylation. Therefore, this plant was selected for further attempts at glycoengineering. Two main approaches were developed in order to humanize N -glycosylation in alfalfa. The first was a knock-down of two plant-specific N -glycan maturation enzymes, β1,2-xylosyltransferase and α1,3-fucosyltransferases, using sense, antisense and RNA interference strategies. In a second approach, with the ultimate goal of rebuilding the whole human sialylation pathway, human β1,4-galactosyltransferase was expressed in alfalfa in a native form or in fusion with a targeting domain from N -acetylglucosaminyltransferase I, a glycosyltransferase located in the early Golgi apparatus in Nicotiana tabacum . Both knock-down and knock-in strategies strongly, but not completely, inhibited the biosynthesis of α1,3-fucose- and β1,2-xylose-containing glycoepitopes in transgenic alfalfa. However, recombinant human β1,4-galactosyltransferase activity in transgenic alfalfa completely prevented the accumulation of the Lewis a glycoepitope on complex N -glycans. |
| |
Keywords: | alfalfa glycoengineering glycosyltransferase Lewis a epitope N-glycosylation plant-made pharmaceutical |
本文献已被 PubMed 等数据库收录! |
|